# Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Source: https://onco.cc/trials/nct02696356/  
OnCo record `nct02696356` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of GRN-1201 run by BrightPath Biotherapeutics, completed.

## Summary

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma is a phase 1 interventional study registered as NCT02696356 by BrightPath Biotherapeutics, with 18 participants enrolled, started 2016-04. Conditions recorded: Melanoma. Interventions recorded: GRN-1201.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02696356
- Phase: 1
- Setting: A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of Intradermal GRN-1201 in HLA-A*02 Subjects With Resected Stage IIb, IIc or III Melanoma
- Sponsor: BrightPath Biotherapeutics
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT02696356: https://clinicaltrials.gov/study/NCT02696356

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [GRN-1201](https://onco.cc/drugs/grn-1201/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02696356.json